Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase commonly known as statins are widely used for treating hypercholesterolemia. However, there is much evidence to suggest that statins may have other properties in addition to their cholesterol-lowering effect. In particular, statins may neutralize post-translational prenylation of vitally important regulatory small GTPases, which are involved in several processes such as tissue fibrosis, cell maturation, apoptosis, immune cell maturation, and immune response. The beneficial effect of statins has been reported in animal and in vitro models as well as in some clinical studies. As they have an acceptable safety profile, statins may be considered, in selected cases, as a valuable concomitant therapy in the treatment of rheumatic and autoimmune disorders.
Abud-Mendoza, C., de la Fuente, H., Cuevas-Orta, E., Baranda, L., Cruz-Rizo, J. and Gonzalez-Amaro, R. ( 2003) Therapy with statins in patients with refractory rheumatic diseases: A preliminary study. Lupus12: 607-611.
2.
Aktas, O., Waiczies, S., Smorodchenko, A., Dorr, J., Seeger, B., Prozorovski, T. et al. (2003) Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J Exp Med197: 725-733.
3.
Aoki, I., Aoki, N., Kawano, K., Shimoyama, K., Maki, A., Homori, M. et al. (1997) Platelet-dependent thrombin generation in patients with hyperlipidemia. J Am Coll Cardiol30: 91-96.
4.
Baecher-Allan, C., Brown, J.A., Freeman, G.J. and Hafler, D.A. ( 2001) CD4+CD25 high regulatory cells in human peripheral blood . J Immunol167: 1245-1253.
5.
Barandier, C., Ming, X.F. and Yang, Z. ( 2003) Small G proteins as novel therapeutic targets in cardiovascular medicine. News Physiol Sci18: 18-22.
6.
Botazzo, G.F., Pujol-Borrel, R., Hanafusa, T. and Feldmann, M. ( 1983) Role of aberrant HLA-DR expression and antigen presentation in induction of endocrine autoimmunity. Lancet2: 1115-1119.
Bulkley, B.H. and Roberts, W.C. ( 1975) The heart in systemic lupus erythematosus and the changes induced in it by the corticosteroid therapy. A study of 36 necropsy patients . Am J Med58: 243-264.
9.
Camera, M., Toschi, V., Comparato, C., Baetta, R., Rossi, F., Fuortes, M. et al. (2002) Cholesterol-induced thrombogenicity of the vessel wall: Inhibitory effect of fluvastatin. Thromb Haemost87: 748-755.
10.
Cipollone, F., Fazia, M., Iezzi, A., Zucchelli, M., Pini, B., De Cesare, D. et al. (2003) Suppression of the functionally coupled cyclooxygenase-2/prostaglandin E synthase as a basis of simvastatin dependent plaque stabilization in humans . Circulation107: 1479-1485.
11.
Clark, D.A. and Coker, R. ( 1998) Transforming growth facto-beta (TGF-β). Int J Biochem Cell Biol30: 293-298.
12.
Cohen, L.H., Pieterman, E., van Leeuwen, R.E., Overhand, M., Burm, B.E., van der Marel, G.A. et al. (2000) Inhibitors of prenylation of Ras and other G-proteins and their application as therapeutics. Biochem Pharmacol60: 1061-1068.
13.
Colicelli, J. ( 2004) Human RAS superfamily proteins and related GTPases. Sci STKE250: RE13.
14.
Colli, S., Eligini, S., Lalli, M., Camera, M., Paoletti, R. and Tremoli, E. ( 1997) Vastatins inhibit tissue factor in cultured human macrophages: A novel mechanism of protection against atherothrombosis. Arterioscler Thromb Vasc Biol17: 265-272.
15.
Comparato, C., Altana, C., Bellosta, S., Baetta, R., Paoletti, R. and Corsini, A. ( 2001) Clinically relevant pleiotropic effects of statins: Drug properties or effects of profound cholesterol reduction? Nutr Metab Cardiovasc Dis11: 328-343.
16.
Corsini, A., Mazzotti, M., Raiteri, M., Soma, M.R., Gabbiani, G., Fumagalli, R. et al. (1993) Relationship between mevalonate pathway and arterial myocyte proliferation: In vitro studies with inhibitors of HMGCoA reductase. Atherosclerosis1001: 117-125.
17.
Corsini, A., Pazzucconi, F., Arnaboldi, L., Pfister, P., Fumagalli, R., Paoletti, R. et al. (1998) Direct effects of statins on the vascular wall . J Cardiovasc Pharmacol31: 773-778.
18.
Costenbader, K.H., Liang, M.H., Chibnik, L.B., Aizer, J., Kwon, H., Gall, V. et al. (2007) A pravastatin dose-escalation study in systemic lupus erythematosus. Rheumatol Int27: 1071-1077.
19.
Cristea, A., Rus, H., Niculescu, F., Bedeleanu, D. and Vlaicu, R. ( 1986) Characterization of circulating immune complexes in heart disease. Immunol Lett13: 45-49.
20.
Dahlback, B. ( 2000) Blood coagulation. Lancet355: 1627-1632.
21.
Daniel, J.L., Dangelmaier, C., Jin, J., Kim, Y.B. and Kunapuli, S.P. ( 1999) Role of intracellular signaling events in ADP-induced platelet aggregation. Thromb Haemost82: 1322-1326.
22.
de Kruif, M.D., Limper, M., Hansen, H.R., de Ruiter, J., Spek, C.A. and van Gorp, E.C.(2009) Effects of a 3-month course of rosuvastatin in patients with systemic lupus erythematosus. Ann Rheum Dis68: 1654.
23.
Esdaile, J.M., Abrahamowicz, M., Grodzicky, T., Li, Y., Panaritis, C., du Berger, R. et al. (2001) Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus . Arthritis Rheum44: 2331-2337.
24.
Esteve, E., Castro, A., Lopez-Bermejo, A., Endrell, J., Ricart, W. and Fernandez-Real, J.M. ( 2007) Serum interleukin-6 correlates with endothelial dysfunction in healthy men independently of insulin sensitivity. Diabetes Care30: 939-945.
25.
Etienne-Manneville, S. and Hall, A. ( 2002) Rho GTPases in cell biology. Nature420: 629-635.
26.
Eto, M., Barandiér, C., Rathgeb, L., Kozai, T., Joch, H., Yang, Z. et al. (2001) Thrombin suppresses endothelial nitric oxide synthase and upregulates endothelin converting enzyme-1 expression by distinct pathways: Role of Rho/ROCK and mitogen-activated protein kinase. Circ Res89: 583-590.
27.
Eto, M., Kozai, T., Cosentino, F., Joch, H. and Lüscher, T.F. ( 2002) Statins prevent tissue factor expression in human endothelial cells: Role of Rho/ Rho-kinase and Akt pathways. Circulation87: 748-755.
28.
Ferreira, G.A., Navarro, T.P., Telles, R.W., Andrade, L.E. and Sato, E.I. ( 2007) Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: An 8 week controlled trial . Rheumatology (Oxford) 46: 1560-1565.
29.
Ferro, D., Basili, S., Alessandri, C., Cara, D. and Violi, F. ( 2000) Inhibition of tissue-factor-mediated thrombin generation by simvastatin. Atherosclerosis149: 111-116.
30.
Frazie, K., Williams, S., Kothapalli, D., Klapser, H. and Grotendorst, G.R. ( 1996) Stimulation of fibroblast cell growth, matrix production, and granulation tissue formation by connective tissue growth factor. J Invest Dermatol107: 404-411.
31.
Fuster, V., Badimon, L., Badimon, J.J. and Chesebro, J.H. ( 1992) The pathogenesis of coronary artery disease and acute coronary syndromes 2. N Engl J Med326: 310-318.
32.
George, J., Afek, A., Keren, P., Herz, I., Goldberg, I., Haklai, R. et al. (2002) Functional inhibition of Ras by s-trans, trans-farnesyl thiosalicylic acid attenuates atherosclerosis in apolipoprotein E knockout mice. Circulation105: 2416-2422.
33.
Glomset, J.A. and Farnsworth, C.C. ( 1994) Role of protein modification reactions in programming interactions between ras-related GTPases and cell membranes. Annu Rev Cell Biol10: 181-205.
34.
Hakamada-Taguchi, R., Uehara, Y., Kuribayashi, K., Numabe, A., Saito, K., Negoro, H. et al. (2003) Inhibition of hydroxymethylglutaryl coenzyme A reductase reduces Th1 development and promotes Th2 development. Circ Res93: 948-956.
35.
Han, K.H., Ryu, J., Hong, K.H., Ko, J., Pak, Y.K., Kim, J.B. et al. (2005) HMG-CoA reductase inhibition reduces monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1 mediated monocyte recruitment in vivo. Circulation111: 1439-1447.
36.
Hanson, J. and Bossingham, D. ( 1998) Lupus-like syndrome associated with simvastatin. Lancet352: 1070.
37.
Heinrich, J. and Assmann, G. ( 1995) Fibrinogen and cardiovascular risk. J Cardiovasc Risk2: 197-205.
38.
Henney, A.M., Wakeley, P.R., Davies, M.J., Foster, K., Hembry, R., Murphy, G. et al. (1991) Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci U S A88: 8154-8158.
39.
Johnsson, H., Nived, O. and Sturfelt, G. ( 1989) Outcome in systemic lupus erythematosus: A prospective study of patients from a defined population. Medicine ( Baltimore) 68: 141-150.
40.
Kanda, H., Hamasaki, K., Kubo, K., Tateishi, S., Yonezumi, A., Kanda, Y. et al. (2002) Antiniflammatory effect of simvastatin in
41.
patients with rheumatoid arthritis. J Rheumatol29: 2024-2026.
42.
Kaneider, N.C., Egger, P., Dunzendorfer, S. and Wiedermann, C.J. ( 2002) Rho-GTPase-dependent platelet-neutrophil interaction affected by HMG-CoA reductase inhibition with altered adenosine nucleotide release and function. Arterioscler Thromb Vasc Biol22: 1029-1035.
43.
Kim, Y.C., Kim, K.K. and Shevach, E.M.(2010) Simvastatin induces Foxp3 T regulatory cells by modulation of transforming growth factor-beta signal transduction. Immunology130: 484-493.
44.
Kotyla, P.J.(2009) Pravastatin, a 3-hydroxy-3-methylglutharyl coenzyme A inhibitor does not show pleiotropic effects in patients with systemic lupus erythematosus . Rheumatol Int29: 353-354.
45.
Kotyla, P.J., Sliwinska-Kotyla, B. and Kucharz, E.J. ( 2006) TNF alpha as a potential target in the treatment of SLE: A Role for the HMG-CoA reductase inhibitor simvastatin. J Rheumatol33: 2361.
46.
Krysiak, R., Okopień, B. and Herman, Z.S. ( 2003) Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes. Drugs63: 1821-1854.
47.
Kwak, B., Mulhaupt, F., Myit, S. and Mach, F. ( 2000) Statins as newly recognized type of immunomodulator. Nat Med6: 1399-1402.
48.
Kwak, B., Mulhaupt, F., Veillard, N., Pelli, G. and Mach, F. ( 2001) The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells. Swiss Med Wkly131: 41-46.
49.
Lawman, S., Mauri, C., Jury, E.C., Cook, H.T. and Ehrenstein, M.R. ( 2004) Atorvastatin inhibits auto-reactive B cell activation and delays lupus development in New Zeland Black/White F1 mice. J Immunol173: 7641-7646.
50.
Leung, B.P., Sattar, N., Crilly, A., Prach, M., McCarey, D.W., Payne, H. et al. (2003) A novel antiinflammatory role for simvastatin in inflammatory arthritis. J Immunol170: 1524-1530.
51.
Li, C., Lim, S.W., Choi, B.S., Lee, S.H., Cha, J.H., Kim, I.S. et al. (2005) Inhibitory effect of pravastatin on transforming growth factor β1-inducible gene h3 expression in a rat model of chronic cyclosporine nephropathy. Am J Nephrol25: 611-620.
52.
Liao, J.K. ( 2002) Isoprenoids as mediators of the biological effect of statins . J Clin Invest110: 285-288.
53.
Libby, P., Ridker, P.M. and Maseri, A. ( 2002) Inflammation and atherosclerosis. Circulation105: 1135-1143.
54.
Lin, H., Xiao, Y., Chen, G., Fu, D., Ye, Y., Liang, L. et al. (2010) HMG-CoA reductase inhibitor simvastatin suppresses Toll-like receptor 2 ligand-induced activation of nuclear factor kappa B by preventing RhoA activation in monocytes from rheumatoid arthritis patients . Rheumatol Int, [Epub ahead of print].
55.
Liu, M.F., Wang, C.R., Fung, L.L. and Wu, C.R. ( 2004) Decreased CD4+CD25+ T cells in peripheral blood of patients with systemic lupus erythematosus. Scand J Immunol59: 198-202.
56.
Liuzzo, G., Kopecky, S.L., Frye, R.L., O’Fallon, W.M., Maseri, A., Goronzy, J.J. et al. (1999) Perturbation of the T-cell repertoire in patients with unstable angina. Circulation100: 2135-2139.
57.
Louneva, N., Huaman, G., Fertala, J. and Jimenez, S.A. ( 2006) Inhibition of systemic sclerosis dermal fibroblast type I collagen production and gene expression by simvastatin. Arthritis Rheum54: 1298-1308.
58.
Mackay, D.J. and Hall, A. ( 1998) Rho GTPases. J Biol Chem273: 20685-20688.
59.
Mahmud, A. and Feely, J. ( 2005) Arterial stiffness is related to systemic inflammation in essential hypertension. Hypertension46: 1118-1122.
60.
Manzi, S., Meilahn, E.N., Rairie, J.E., Conte, C.G., Medsger Jr, T.A., Jansen-McWilliams, L. et al. (1997) Age specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham Study. Am J Epidemiol145: 408-415.
61.
Maradit-Kremers, H., Crownson, C.S., Nicola, P.J., Ballman, K.V., Roger, V.L., Jacobsen, S.J. et al. (2005) Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: A population-based cohort study . Arthritis Rheum52: 402-411.
62.
McCarey, D.W., McInnes, I.B., Madhok, R., Hampson, R., Scherbakov, O., Ford, I. et al. (2004) Trial of atorvastatin in rheumatoid arthritis (TARA): Double blind, randomized placebo controlled trial. Lancet363: 2015-2021.
63.
Meroni, P.L. and Tremoli, E. ( 2003) Modulation of adhesion molecule expression on endothelial cells: To be or not to be? J Thromb Haemost1: 2280-2282.
64.
Mezzetti, A. ( 2005) Pharmacological modulation of plaque instability. Lupus14: 769-772.
65.
Musiał, J., Undas, A., Undas, R., Brozek, J. and Szczeklik, A. ( 2001) Treatment with simvastatin and low-dose aspirin depresses thrombin generation in patients with coronary heart disease and borderline-high cholesterol levels. Thromb Haemost85: 221-225.
66.
Mustafa, A., Nityanand, S., Berglund, L., Lithell, H. and Lefvert, A.K. ( 2000) Circulating immune complexes in 50-year-old men as a strong and independent risk factor for myocardial infarction. Circulation102: 2576-2581.
67.
Navab, M., Berliner, J.A., Watson, A.D., Hama, S.Y., Territo, M.C., Lusis, A.J. et al. (1996) The yin and yang of oxidation in the development of fatty streak: A review based on 1994 George Lymann Duff Memorial Lecture . Arterioscler Thromb Vasc Biol16: 831-842.
68.
Petri, M. ( 2000) Detection of coronary artery disease and the role of traditional risk factors in the Hopkins lupus cohort. Lupus9: 170-175.
69.
Pierre-Paul, D. and Gahtan, V. ( 2003) Noncholesterollowering effects of statins. Vasc Endovascular Surg37: 301-313.
70.
Porreca, E., Di, F.C., Baccante, G., Di, N.M. and Cuccurullo, F. ( 2002) Increased transforming growth factor-beta (1) circulating levels and production in human monocytes after 3-hydroxy-3-methyl-glutarylcoenzyme a reductase inhibition with pravastatin. J Am Coll Cardiol39: 1752-1757.
71.
Postlethwaite, A.E. ( 1995) Role of T cells and cytokines in effecting fibrosis. Int Rev Immunol12: 247-258.
72.
Riessen, R., Axel, D.I., Fenchel, M., Herzog, U.U., Rossmann, H. and Karsch, K.R. ( 1999) Effect of HMG-CoA reductase inhibitors on extracellular matrix expression in human vascular smooth cells. Basic Res Cardiol94: 322-332.
73.
Roman, M.J., Salmon, J.E., Sobel, R., Lockshin, M.D., Sammaritano, L., Schwartz, J.E. et al. (2001) Prevalance and relation to risk factors of carotid atherosclerosis and left ventricular hypertrophy in systemic lupus erythematosus and antiphospholipid antibody syndrome. Am J Cardiol87: 663-666.
74.
Romano, M., Diomede, L., Sironi, M., Massimiliano, L., Sottocorno, M., Polentarutti, N. et al. (2000a) Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest80: 1095-1100.
75.
Romano, M., Mezzetti, A., Marulli, C., Ciabattoni, G., Febo, F., Di Ienno, S. et al. (2000b) Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: Role of nitric oxide. J Investig Med48: 183-189.
76.
Rosenbloom, J., Saitta, B., Gaidarova, S., Sandorfi, N., Rosenbloom, J.C., Abrams, W.R. et al. (2000) Inhibition of type I gene expression in normal and systemic sclerosis fibroblasts by a specific inhibitor of geranylgeranyl transferaseI. Arthritis Rheum43: 1624-1632.
77.
Rosenson, R.S. and Tangney, C.C. ( 1998) Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction. JAMA279: 1643-1650.
78.
Rosenson, R.S., Tangney, C.C. and Schaefer, E.J. ( 2001) Comparative study of HMG-CoA reductse inhibitors on fibrinogen . Atherosclerosis155: 463-466.
79.
Ross, R. ( 1999) Atherosclerosis an inflammatory disease. N Eng J Med340: 115-126.
80.
Ryan, S.T., Koteliansky, V.E., Gotwals, P.J. and Lindner, V. ( 2003) Transforming growth factor-beta-dependent events in vascular remodeling following arterial injury. J Vasc Res40: 37-46.
81.
Sadeghi, M.M., Tiglio, A., Sadigh, K., O’Donnell, L., Collinge, M., Pardi, R. et al. (2001) Inhibition of interferon-gamma-mediated microvascular endothelial cell major histocompatibility complex class II gene activation by HMG-CoA reductase inhibitors. Transplantation71: 1262-1268.
82.
Schror, K. ( 1995) Antiplatelet drugs. A comparative review. Drugs50: 7-28.
83.
Somlyo, A.P. and Somlyo, A.V. ( 2000) Signal transduction by G-proteins, Rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II. J Physiol522: 177-185.
84.
Song, J.C. and White, C.M. ( 2001) Do HMG-CoA reductase inhibitors affect fibrinogen. Ann Pharmacother35: 236-241.
85.
Szczeklik, A., Musiał, J., Undas, A., Gajewski, P., Gόra, P. and Swadźba, J. ( 1999) Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia . J Am Coll Cardiol33: 1286-1293.
86.
Takai, Y., Sasaki, T. and Matozataki, T. ( 2001) Small GTP-binging proteins. Physiol Rev81: 153-208.
87.
Takemoto, M. and Liao, J.K. ( 2001) Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol11: 328-343.
88.
Tan, A., Levrey, H., Dahm, C., Polunovsky, V.A., Rubins, J., Bitterman, P.B. et al. (1999) Lovastatin induces fibroblast apoptosis in vitro and in vivo: A possible therapy for fibroproliferative disorders. Am J Respir Crit Care Med159: 220-227.
89.
Urowitz, M.B., Bookman, A.A., Koehler, B.E., Gordon, D.A., Smythe, H.A. and Ogryzlo, M.A. ( 1976) The bimodal mortality pattern of systemic lupus erythematosus . Am J Med60: 221-225.
90.
Valencia, X., Yarboro, C., Illei, G. and Lipsky, P.E. ( 2007) Deficient CD4+CD25 high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol178: 2579-2588.
91.
van Haelst, P.L., van Doormaal, J.J., May, J.F., Gans, R.O., Crijns, H.J. and Cohen-Tervaert, J.W. ( 2001) Secondary prevention with fluvastatin decreases levels of adhesion molecules, neopterin and C reactive protein. Eur J Intern Med12: 503-509.
92.
Varga, J., Rosenbloom, J. and Jimenez, S.A. ( 1987) Transforming growth factor beta (TGF-beta) causes a persistent increase in steady-state amounts of type I and type III collagen and fibronectin mRNAs in normal human dermal fibroblasts. Biochem J247: 597-604.
93.
Vaughan, C.J. and Gotto, A.M. ( 2004) Update on statins: 2003. Circulation110: 886-892.
94.
Vaughan, C.J., Gotto, A.M. and Basson, C.T. ( 2000) The evolving role of statins in the management of atherosclerosis . J Am Coll Cardiol35: 1-10.
95.
Warkentin, T.E. ( 1995) Hemostasis and atherosclerosis. Can J Cardiol11(Suppl C): 29-34.
96.
Watts, G.M., Beurskens, F.J., Martin-Padura, I., Ballantyne, C.M., Klickstein, L.B., Brenner, M.B. et al. (2005) Manifestations of inflammatory arthritis are critically dependent on LFA-1. J Immunol174: 3668-3675.
97.
Watts, K.L., Cottrell, E., Hoban, P.R. and Spiteri, M.A. ( 2006) RhoA signaling modulates cyclin D1 expression in human lung fibroblasts: Implication for idiopathic pulmonary fibrosis. Respir Res7: 88-102.
98.
Watts, K.L. and Spiteri, M. ( 2004) Connective tissue growth factor expression and induction by transforming growth factor is abrogated by simvastatin via Rho signaling mechanism. Am J Physiol Lung Cell Mol Physiol287: L1323-L1332.
99.
Weitz-Schmidt, G., Welzenbach, K., Brinkmann, V., Kamata, T., Kallen, J., Bruns, C. et al. (2001) Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med7: 687-692.
100.
Yokota, K., Miyazaki, T., Hirano, M., Akiyama, Y. and Mimura, T. ( 2006) Simvastatin inhibits production of interleukin 6 (IL-6) and IL-8 and cell proliferation induced by tumor necrosing factor-α in fibroblast-like synoviocytes from patients with rheumatoid arthritis. J Rheumatol33: 463-471.
101.
Yokota, K., Miyoshi, F., Miyazaki, T., Sato, K., Yoshida, Y. and Asanuma, Y. ( 2008) High concentration simvastatin induces apoptosis in fibroblast-like synoviocytes from patients with rheumatoid arthritis. J Rheumatol35: 193-200.
102.
Youssef, S., Stüve, O., Patarroyo, J.C., Ruiz, P.J., Radosevich, J.L., Hur, E.M. et al. (2002) The HMGCoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature420: 78-84.
103.
Zhang, F.L. and Casey, P.J. ( 1996) Protein prenylation: Molecular mechanism and functional consequences. Annu Rev Biochem65: 241-269.
